Di Lernia V, Bonamonte D, Lasagni C, Belloni Fortina A, Cambiaghi S, Corazza M, Di Nuzzo S, Gisondi P, Panzone M, Guarneri C, Neri I (2016) Effectiveness and safety of acitretin in children with plaque psoriasis: a multicenter retrospective analysis
Specifically, the biosynthesis of amino acids (37 KOs), was significantly down-represented, including cysteine and methionine metabolism ( metA , metB , metK , mtnN , thrB , cysK , patB and L-serine dehydratase ), the biosynthesis of lysine ( dapA , dapB , dapE , dapH , dapL , argD , patA and lysA ), the metabolism of histidine ( hisA , hisB , hisE , hisH and hisI ), glycine, serine and threonine ( glyA , thrB , thrC and L-serine dehydratase ), alanine, aspartate and glutamate (asnA, asnB and argH), the biosynthesis of phenylalanine, tyrosine and tryptophan ( aroD and aroE ) and the biosynthesis of arginine ( argD and argH )

Full disclaimer 1.AOD-9604 is a 16-amino acid peptide fragment derived from human growth hormone (hGH residues 177-191) with added tyrosine, developed by Metabolic Pharmaceuticals for obesity treatment 2.Proposed mechanism: selective stimulation of lipolysis (fat breakdown) and inhibition of lipogenesis (fat formation) without growth hormone-like effects on IGF-1 or blood glucose 3.Failed Phase 2b clinical trial for obesity (2007)did not demonstrate statistically significant weight loss versus placebo, terminating clinical development for this indication 4.Received FDA "Generally Recognized as Safe" (GRAS) designation in 2023 as a food substance, but this is NOT a drug approval and does not establish efficacy for weight loss 5.Regulatory status: not FDA-approved as a drug, prohibited by WADA, and insufficient evidence for weight loss efficacy
RELATED: Why do dogs pant